<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008616</url>
  </required_header>
  <id_info>
    <org_study_id>Velo-201</org_study_id>
    <nct_id>NCT03008616</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe Preeclampsia</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Velo Bio, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Velo Bio, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of Digoxin immune fab in addition to expectant management in the
      treatment of severe preeclampsia as compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age</measure>
    <time_frame>36 weeks corrected gestational age</time_frame>
    <description>Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum creatinine</measure>
    <time_frame>From treatment initiation to 24 hours post first dose</time_frame>
    <description>Maternal change from baseline in serum creatinine to 24 hours post first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary edema</measure>
    <time_frame>From treatment initiation until completion of treatment phase (up to 4 days)</time_frame>
    <description>Maternal incidence of pulmonary edema during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of mothers with modified early obstetric warning score &gt;= 3 at 24 hours post first dose</measure>
    <time_frame>24 hours post first dose</time_frame>
    <description>Proportion of mothers with modified early obstetric warning score &gt;= 3 at 24 hours post final dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery latency</measure>
    <time_frame>From treatment initiation until delivery</time_frame>
    <description>Time from start of treatment until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-hypertensive use during treatment</measure>
    <time_frame>From treatment initiation until completion of treatment phase (up to 4 days)</time_frame>
    <description>Use of or change in anti-hypertensive use during the treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Severe Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Digoxin immune fab (DigiFab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Digoxin immune fab 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, 30 minute IV infusion, every 6 hours x 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Digoxin immune fab</intervention_name>
    <description>Digoxin immune fab 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days</description>
    <arm_group_label>Digoxin immune fab (DigiFab)</arm_group_label>
    <other_name>DigiFab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline, 30 minute IV infusion, every 6 hours x 4 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fetal gestational age 23 0/7 to 31 6/7 weeks

          -  Treated with expectant management

          -  Meets modified ACOG criteria for severe preeclampsia

          -  Willing and able to provide written, informed consent

        Exclusion Criteria:

          -  Decision to deliver within 24 hours has been made

          -  Weight &gt; 150 kg

          -  Eclampsia

          -  Significant antecedent obstetrical problems

          -  Clinically significant fetal anomaly or chromosomal abnormalities

          -  Chronic renal disease

          -  Active hepatic disease, antiphospholipid antibody syndrome, or lupus

          -  Unstable medical or psychiatric disorder

          -  Need for use of digitalis like products

          -  History of anaphylactic allergic reactions

          -  Prior use of antibodies/fab fragments from sheep

          -  Serum creatinine ≥ 2.0 mg/dL

          -  Platelet count &lt; 50,000

          -  Pulmonary edema

          -  Estimated fetal weight &lt; 5th percentile
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Rigdon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Velo Bio, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuki Prescott, MPT</last_name>
    <phone>919-460-9500</phone>
    <phone_ext>208</phone_ext>
    <email>yprescott@quatrobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Armistead, RN</last_name>
      <email>marmistead@health.southalabama.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Watching Over Mothers and Babies</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Mercer</last_name>
      <email>mercer.diane@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brown</last_name>
      <email>jenbrown@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Moore</last_name>
      <email>jmoore20@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Children's Maternal Fetal Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Waldon, RN</last_name>
      <email>christina.waldon@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Hutchinson, RN</last_name>
      <phone>318-675-5592</phone>
      <email>dthomp4@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Brengle, RN</last_name>
      <email>LBrengle@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Healthcare</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Cormier, RN</last_name>
      <email>Sharon.Cormier@umassmemorial.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Belk</last_name>
      <email>sbelk@umc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheree White</last_name>
      <email>Sheree.White@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorrie Mason</last_name>
      <email>lorrie@rocob.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UTMB - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Wilson, RN</last_name>
      <email>marwilso@UTMB.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Castelan-Balbuena</last_name>
      <email>Karen.CastelanBalbuena@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Cortez</last_name>
      <email>BNC9XW@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Herdeman</last_name>
      <phone>414-805-6936</phone>
      <email>cherdeman@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

